NEUMORA THERAPEUTICS, INC. Stock-Based Compensation
NEUMORA THERAPEUTICS, INC. (NMRA) reported Stock-Based Compensation of $14.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $7.18M, a 0.27% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $7.41M, a 20.58% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $7.41M, a 25.20% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $5.98M, a 39.88% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $29.88M, a 25.29% decline from fiscal 2024.
- NEUMORA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $39.99M, a 131.96% increase from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $17.24M, a 107.76% increase from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $8.30M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $14.59M 10-Q · filed 2026-08-14 | $22.00M derived: sum of 3 quarters · filed 2026-08-14 | $27.98M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $7.41M 10-Q · filed 2026-05-07 | $14.81M derived: sum of 2 quarters · filed 2026-05-07 | $20.79M derived: sum of 3 quarters · filed 2026-05-07 | $27.96M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $7.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $13.39M derived: sum of 2 quarters · filed 2026-03-30 | $20.55M derived: sum of 3 quarters · filed 2026-08-14 | $29.88M 10-K · filed 2026-03-30 |
| 2025-09-30 | $5.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $13.14M derived: sum of 2 quarters · filed 2026-08-14 | $22.47M 10-Q · filed 2025-11-06 | $32.37M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $7.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $16.49M 10-Q · filed 2026-08-14 | $26.39M derived: sum of 3 quarters · filed 2026-08-14 | $36.34M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $9.32M 10-Q · filed 2026-05-07 | $19.23M derived: sum of 2 quarters · filed 2026-05-07 | $29.17M derived: sum of 3 quarters · filed 2026-05-07 | $41.94M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $19.85M derived: sum of 2 quarters · filed 2026-03-30 | $32.62M derived: sum of 3 quarters · filed 2026-03-30 | $39.99M 10-K · filed 2026-03-30 |
| 2024-09-30 | $9.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $22.71M derived: sum of 2 quarters · filed 2025-11-06 | $30.09M 10-Q · filed 2025-11-06 | $36.14M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $12.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $20.14M 10-Q · filed 2025-08-06 | $26.19M derived: sum of 3 quarters · filed 2025-08-06 | $32.64M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $7.37M 10-Q · filed 2025-05-12 | $13.42M derived: sum of 2 quarters · filed 2025-05-12 | $19.88M derived: sum of 3 quarters · filed 2025-05-12 | $22.42M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $6.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $12.50M derived: sum of 2 quarters · filed 2025-03-03 | $15.04M derived: sum of 3 quarters · filed 2025-03-03 | $17.24M 10-K · filed 2025-03-03 |
| 2023-09-30 | $6.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $8.99M derived: sum of 2 quarters · filed 2024-11-12 | $11.19M 10-Q · filed 2024-11-12 | $13.98M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $2.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.74M 10-Q · filed 2024-08-06 | $7.53M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2023-03-31 | $2.19M 10-Q · filed 2024-05-07 | $4.99M derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $8.30M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $5.51M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |